The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: BAT On Fire After Half Year Earnings Surge

Thu, 26th Jul 2018 10:55

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------British American Tobacco, up 5.2%. The Dunhill, Kent and Lucky Strike cigarette maker said interim profit, revenue and cigarette volumes all grew strongly after its acquisition of Reynolds American and expects another "good" year of growth. For the six months ended June, pretax profit widened 31% to GBP3.97 billion from GBP3.03 billion the year prior. This was after revenue rose 57% to GBP11.64 billion from GBP7.42 billion the year before. Cigarette volumes jumped 10% to 345.0 billion sticks in the period. Performance was helped by its acquisition of Reynolds American Inc in July 2017. On a pro-forma basis - assuming BAT had owned Reynolds through the whole of 2017 - revenue rose 1.9% and cigarette volumes fell 3.1%.RELX, up 3.8%. The information and analytics group reported a flat performance in the first half of its current financial year, but said it is confident in delivering a year of earnings growth. The company said the six months to June 30 saw revenue down 1.4% to GBP3.65 billion, from GBP3.70 billion the year before, while adjusted profit before tax remained broadly flat at GBP1.05 billion. RELX declared an interim dividend increase of 6.0% to 12.40 pence from 11.70p paid for the same period a year earlier. The company said as it enters the second half of 2018, it is confident in delivering another year of underlying revenue, profit, and earnings growth.Smith & Nephew, up 3.7%. The medical devices maker reported a rise in interim revenue but a fall in profit, as it progressed a programme designed to generate annualised cost savings of USD50 million. Revenue for the first half of the year rose 4.3% to USD2.44 billion from USD2.34 billion, though pretax profit slipped 11% to USD341 million from USD383 million. The revenue growth included a foreign exchange tailwind of 3%, with sales up 1% on an underlying basis.AstraZeneca, up 2.8%. The Anglo-Swedish drugmaker reported a fall in interim revenue and profit, but held its annual guidance. Total revenue for the first half of the year fell 1% at actual exchange rates, down 5% at constant currencies, to USD10.33 billion. Product sales rose 2% at actual exchange rates to USD10.02 billion but externalisation revenue - which includes royalties and milestone payments - was down 53% to USD318 million. Astra kept its interim dividend flat at USD0.90 per share, reiterating its annual guidance.----------FTSE 100 - LOSERS----------SSE, down 5.5%. The utility stock went ex-dividend meaning new buyers no longer qualify for the latest payout.Schroders, down 3.7%. The asset manager lifted its interim dividend payout on the back of a rise in earnings and total assets under management. The company, however, added that no new business was generated by the asset management unit in the first half as inflows from institutional clients were offset by outflows in the intermediary sales channel. The wealth management unit recorded net inflows of GBP1.20 billion in the period, however. Total assets under management and administration as at June 30 totalled GBP449.4 billion, up from GBP447.0 billion as at December 31. GlaxoSmithKline, down 3.0%. The drugmaker said an advisory panel of US Food & Drug Administration has recommended against approval of mepolizumab for the treatment of chronic obstructive pulmonary disease, a type of lung condition that causes breathing difficulties. Glaxo said the Pulmonary Allergy Drugs Advisory Committee has voted that the risk-benefit profile was not adequate to support approval of mepolizumab as an add-on treatment for the reduction of exacerbations in patients with chronic obstructive pulmonary disease. Royal Dutch Shell 'B', down 2.5%, Shell 'A', down 2.5%. The oil major announced a share buyback worth USD25 billion, though the company missed expectations despite a sharp rise in earnings. Shell also lowered its production guidance for the third quarter in both its Upstream and Integrated Gas businesses, partly due to its current divestment programme. Shell launched a buyback of "at least" USD25 billion for the period 2018 to 2022. For the first tranche of this, Shell is to purchase shares up to USD2 billion of shares over a period of three months. Free cash flow for the quarter was USD9.53 billion, well below the USD12.16 billion a year prior, though up from the first quarter's USD5.18 billion. In the first half, free cash flow was USD14.71 billion, down from USD17.34 billion. Compass Group, down 2.3%. The contract caterer said it continues to trade well, though with margins slightly behind last year with a "challenging" cost and volume environment in the UK. In the company's financial third quarter, overall organic revenue grew 5.7% - up 5.1% excluding the impact of Easter, which fell in Compass's second quarter - driven by strong net new business in North America, an acceleration in Europe and good progress in Rest of World. ----------FTSE 250 - WINNERS----------Vesuvius, up 8.1%. The molten metal flow engineering firm reported a record trading profit as its end markets remained favourable in the first half, with the company now expecting to outperform consensus for the full-year. The group said revenue for the first half of 2018 rose 7.9% to GBP897.0 million from GBP831.5 million last year, as pretax profit soared 44% to GBP87.8 million from GBP60.8 million. Trading profit grew 15% to a "record" GBP99.6 million, as return on sales improved by 70 basis points to 11.1% from 10.4%.Renishaw, up 3.0%. The engineer hiked its annual payout following strong earnings growth across all of its geographies. The group reported a pretax profit of GBP155.2 million for the year to the end of June, up by a third from GBP117.1 million profit posted the year before. Revenue grew 14% to GBP611.5 million from GBP536.8 million. On a constant currency basis, it was 18% higher year-on-year. The company said revenue growth was boosted by a strong performance across all regions and divisions. Continental Europe came in as the best performer during the year with revenue up 19% to GBP154.2 million from GBP129.9 million.National Express, up 2.5%. The transport operator delivered its "best ever" half-year profit as it grew revenue in all divisions. For the six months to June 30, the company posted pretax profit of GBP80.1 million, improved to GBP64.6 million a year ago. Revenue rose 3.2% to GBP1.20 billion from GBP1.17 billion year-on-year, driven in particular by the growth in North America and in the company's Spanish division ALSA. All the company's divisions increased commercial passengers, with the group carrying nearly 1.5% more year-on-year, National Express said.----------FTSE 250 - LOSERS----------Cobham, down 10%. The defence and aerospace equipment supplier said it expects to take a GBP40 million hit related to its US KC-46 tanker programme, with Boeing Co currently withholding the payment of invoices. Cobham said while there has been progress on the programme, US aerospace firm Boeing has made "as yet unquantified damages assertions" relating to the programme. Consequently, Boeing is withholding payment of Cobham's KC-46 CDS and WARP invoices. Cobham said it is formally disputing Boeing's claims. Additionally, completion of CDS qualification has taken longer and been "more challenging" than expected.Intu Properties,down 6.5%. The shopping centre operator said net rental income and occupancy remained stable despite net asset value falling sharply in a weak UK retail environment. For the six months ended June, net asset value per share fell to 362 pence from 411p at the end of 2017. Net rental income also dropped modestly to GBP223.1 million from GBP226.2 million the year prior. Occupancy fell to 96.6% at the end of June, from 97.0% six months earlier and 96.8% the year prior. The proportion of tenants trading in administration, however, fell to 0.3% from 0.6% six months earlier. Intu proposed a flat interim dividend per share at 4.6p.Howden Joinery, down 5.3%. The kitchen supplier said new product initiatives and higher costs of goods dented first half profit growth. The company also said revenue for the core UK division in the first four weeks of second half to July 14 increased by 5.3% and overall expectations for the full year remain unchanged. For the 24 weeks to June 16, the company recorded pretax profit of GBP68.8 million, up from GBP65.6 million in the year ago period, on a revenue of GBP619.4 million and GBP553.0 million, respectively. The core UK unit delivered revenue of GBP604.7 million, up from GBP539.5 million a year ago. Gross profit margin fell to 61.3% from 64.1% due to sales initiatives and increases in costs of goods sold. The company expects inflationary pressures on the costs of goods sold to continue for the remaining part of 2018.----------
More News
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.